Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.66 |
| ▸ | RAB9A | P51151 | 9/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 4/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.60 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634593 | 0.91 | CHEK2 (0.62) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL3563890 | 0.89 | CHEK2 (0.65) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL2178266 | 0.86 | NPC1 (0.88) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL29386825 | 0.86 | NPC1 (0.88) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL6544064 | 0.84 | MPL (0.59) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL24295036 | 0.84 | NPC1 (0.84) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL13137726 | 0.83 | NPC1 (0.66) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL5023990 | 0.83 | NPC1 (0.68) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL14531391 | 0.83 | NPC1 (0.66) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL2103768 | 0.83 | NPC1 (0.66) | NPC1RAB9AGAAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4192880-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | KANEBO, LTD. (JP) | 1980-03-11 | — | — | US | claimed |
| JP-53127475-A | — | — | None | — | — | JP | disclosed |
| US-12195432-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2024137505-A2 | METHOD OF IMPROVING CELL FITNESS IN AN EX-VIVO CELL POPULATION | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230192626-A1 | NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192626-A1 | NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192626-A1 | NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2021242790-A1 | NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-30 | — | — | US | disclosed |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-03-04 | — | — | US | disclosed |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020033359-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-02-13 | — | — | WO | disclosed |
| US-8198307-B2 | Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-06-12 | — | — | US | disclosed |
| US-20100145054-A1 | IMIDAZOLE DERIVATIVES HAVING ARYL PIPERIDINE SUBSTITUENT, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-06-10 | — | — | US | disclosed |
| US-6712262-B2 | BENZIMIDAZOLE AND IODINE COMPOUNDS | TAMURAKAKEN CORPORATION (JP) | 2004-03-30 | — | — | US | disclosed |
| US-4192880-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | KANEBO, LTD. (JP) | 1980-03-11 | — | — | US | disclosed |
| US-4188486-A | 2-Substituted benzimidazole compounds | KANEBO, LTD. (JP) | 1980-02-12 | — | — | US | disclosed |
| JP-S53127475-A | NOVEL BENZIMIDAZOLE COMPOUND AND ITS PREPARATION | KANEBO LTD | 1978-11-07 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | NPC1 379/4885RAB9A 1910/4885GAA 1324/4885 |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | NPC1 989/4885RAB9A 2214/4885GAA 382/4885 |
| US-20230192626-A1 | NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | EPHX1, EPHX2, NCEH1 | NPC1 673/4885RAB9A 3142/4885GAA 612/4885 |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | NPC1 502/4885RAB9A 2015/4885GAA 1555/4885 |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | NPC1 502/4885RAB9A 2015/4885GAA 1555/4885 |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | NPC1 379/4885RAB9A 1910/4885GAA 1324/4885 |
| US-12195432-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | NPC1 989/4885RAB9A 2214/4885GAA 382/4885 |
| US-20100145054-A1 | IMIDAZOLE DERIVATIVES HAVING ARYL PIPERIDINE SUBSTITUENT, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | TYR, MCHR1, MCHR2 | NPC1 223/4885RAB9A 687/4885GAA 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.